Lv4
480 积分 2023-06-30 加入
Olezarsen for Managing Severe Hypertriglyceridemia
22天前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
1个月前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
1个月前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
2个月前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2个月前
已完结
Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial
2个月前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
2个月前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
2个月前
已完结
皖公网安备34019202002308
